The invention relates (i) to pyridine-pyridinone derivatives with the formula (I): where R1 is a hydrogen atom or a (C1-C4)alkyl group R2 is a (CH2)n-B group, in which n = 0, 1, 2, 3 or 4 and B is a (C3-C5)cycloalkyl group, a (C1-C4)alkyl group or a (C1-C4)alkoxy group Y, Z, V and W are, independently from one another, a -CH- group, a carbon atom, a heteroatom or no atom, with the understanding that the cycle, which includes V, W, Y and Z, is a cycle including 5 or 6 members, with the understanding that the dotted lines in said cycle indicate that the resulting cycle is an aromatic cycle and with the understanding that said cycle includes 0, 1 or 2 heteroatoms R3 and R4 are, independently from one another, identical or different groups selected among a hydrogen atom and a straight (C1-C4)alkyl group, or form a (C3-C5)cycloalkyl group together with the carbon to which the former are bonded m is an integer equal to 1, 2, 3 or 4 R5 is a hydrogen atom or a (C1-C4)alkyl group R6 is a (CH2)n-L group where n = 0, 1, 2 or 3, and L is a group selected among aryls with 6 carbon atoms, heteroaryls having 5 or 6 members, the saturated heterocycles including 5, 6 or 7 members or forming a heterocycle group together with the nitrogen atom to which the former are linked. The invention also relates (ii) to the preparation of said derivatives, and (iii) to the therapeutic use thereof as inhibitors of kinase activity in receptors having PDGF ligands and/or receptors with the FLT3 ligand.Linvention se rapporte (i) à des dérivés de pyridino-pyridinones répondant à la formule (I) : dans laquelle, R1 représente un atome dhydrogène ou un groupe (C1 -C4)alkyle R2 représente un groupement -(CH2)n-B où n=0, 1, 2, 3 ou 4 et B représente un groupe (C3-C5)cycloalkyle, un groupe (C1 -C4)alkyle ou un groupe (C1 -C4)alcoxy Y, Z, V et W représentent, indépendamment les uns des autres un groupe -CH-, un atome de carbone, un hétéroatome ou pas datome, étant entendu que le cycle, dans lequel V, W, Y e
